Resource centre

Main menu

13 results

mRNA

Brochure
Introductory guide: unlocking the biopharma development pipeline with Oxford Nanopore
April 16 2025
Case study
Case study: revealing hidden biology with isoform-level single-cell transcriptomics
November 6 2024
Publication
Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines
April 16 2025
Publication
Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario
September 6 2025
Case study
Nanopore sequencing improves the characterisation of mutations driving blood cancer
June 16 2023
Publication
Nanopore direct RNA sequencing of human transcriptomes reveals the complexity of mRNA modifications and crosstalk between regulatory features
May 12 2025
Publication
mRNA m5C alteration in azacitidine demethylation treatment of acute myeloid leukaemia
December 17 2024
Poster
Mapping the yeast mitochondrial transcriptomes by direct RNA sequencing
June 4 2018
Poster
Know, monitor and document bioproduction using Direct RNA Sequencing
April 10 2024
Getting started guide
Getting started guide: biopharma
October 15 2025
Publication
Genetic regulation of nascent RNA maturation revealed by direct RNA nanopore sequencing
August 29 2024
Case study
Case study: delivering ‘unique insights’ into infection with direct RNA sequencing
November 6 2024
Publication
Assessing mRNA and sgRNA quality for cell and gene therapy applications using nanopore direct RNA sequencing
March 6 2026

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Modern slavery policy Accessibility

About Oxford Nanopore

© 2008 - 2026 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, AmPORE-TB, EPI2ME, GridION, MinION, MinKNOW, PromethION, P2 Solo, and P2 are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries. Information contained herein may be protected by copyright, patents or patents pending of Oxford Nanopore Technologies plc. All other brands and names contained are the property of their respective owners. Oxford Nanopore Technologies products are RUO. Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in‐vitro diagnostic devices in some jurisdictions, please check individual product labelling.

ONT plc is a member of the producer compliance scheme run by ERP UK Ltd, who manage the submission of documentation in support of WEEE compliance for ONT plc’s manufacture and supply of Electrical and Electronic equipment in the UK.

ONT’s WEEE PRN is WEE/MM3828AA. See attached certificate for the submission period 2022.

Select Language

Discover nanopore sequencing

Explore products

Research

Techniques

Focus areas

Resources

Documentation

Nanopore Learning

Company

News & Events

Global partners

Resource Centre

Introductory guide: unlocking the biopharma development pipeline with Oxford Nanopore

Case study: revealing hidden biology with isoform-level single-cell transcriptomics

Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines

Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario

Nanopore sequencing improves the characterisation of mutations driving blood cancer

Nanopore direct RNA sequencing of human transcriptomes reveals the complexity of mRNA modifications and crosstalk between regulatory features

mRNA m5C alteration in azacitidine demethylation treatment of acute myeloid leukaemia

Mapping the yeast mitochondrial transcriptomes by direct RNA sequencing

Know, monitor and document bioproduction using Direct RNA Sequencing

Getting started guide: biopharma

Genetic regulation of nascent RNA maturation revealed by direct RNA nanopore sequencing

Case study: delivering ‘unique insights’ into infection with direct RNA sequencing

Assessing mRNA and sgRNA quality for cell and gene therapy applications using nanopore direct RNA sequencing

Filter

Products

Research areas

Techniques

Products

Research areas

Techniques

Getting started

Quick links

About Oxford Nanopore

Focus areas

Resource Centre

Introductory guide: unlocking the biopharma development pipeline with Oxford Nanopore

Case study: revealing hidden biology with isoform-level single-cell transcriptomics

Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines

Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario

Nanopore sequencing improves the characterisation of mutations driving blood cancer

Nanopore direct RNA sequencing of human transcriptomes reveals the complexity of mRNA modifications and crosstalk between regulatory features

mRNA m5C alteration in azacitidine demethylation treatment of acute myeloid leukaemia

Mapping the yeast mitochondrial transcriptomes by direct RNA sequencing

Know, monitor and document bioproduction using Direct RNA Sequencing

Getting started guide: biopharma

Genetic regulation of nascent RNA maturation revealed by direct RNA nanopore sequencing

Case study: delivering ‘unique insights’ into infection with direct RNA sequencing

Assessing mRNA and sgRNA quality for cell and gene therapy applications using nanopore direct RNA sequencing

Filter

Products

Research areas

Techniques

Products

Research areas

Techniques

Related content

Getting started

Quick links

About Oxford Nanopore